FDA to address deficiencies in post-marketing surveillance

Share this article:
Over 80% of the manufacturers that submitted postmarketing information to FDA met their obligations, despite weaknesses in FDA's monitoring and tracking of postmarketing requirements (PMR) and postmarketing commitments (PMC), an FDA-commissioned study found.

“Most sponsors take the completion of PMRs and PMCs very seriously,” said John Jenkins, director, office of new drugs, CDER, in a media briefing this morning, adding that FDA regrets the shortage of staff and resources that contributed to the backlog.

As a result of the study – and new financial allowances from Congress – FDA has “already initiated steps to improve efficiency,” said Jenkins. At the end of July, FDA created a new database in the Document Archiving and Records Retention System (DARRTS) that includes “increased capabilities for data capture, tracking, and generating reports related to postmarketing studies,” according to a statement. Additionally, FDA established new positions – a postmarkeing study development coordinator and a tracking coordinator – within each new drug division.

The study (here, in pdf) reviewed 1,531 PMRs/PMCs and found that 51% of them had an inaccurate status and required an update. After the statuses were updated, 569 (36%) of the PMRs/PMCs were changed to “submitted” status. Jenkins said FDA has already taken action on 201 of those, and that 151 were fulfilled, 19 released, 18 changed to a new category, and 13 were deemed unacceptable. Additionally, 244 of the 1,531 PMRs/PMCs in the backlog have since been closed, said Jenkins.    

FDA contracted Booz Allen Hamilton to review its backlog of PMRs and PMCs going back to September 27, 2007, responding to Section 921 of the Food and Drug Administration Amendments Act of 2007. FDA's fiscal year ends on September 30, and Section 921 requires FDA to review its entire backlog on an annual basis. The study looked at the backlog through February 22, 2009.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?